Acquisitions - Preliminary Purchase Price Allocation (Details) - USD ($)	5 Months Ended
	Sep. 30, 2022	Apr. 18, 2022
Purchase price allocation:
Intangible asset - definite-lived (Note 7)	$ 9,700,000
Goodwill	3,467,748
Elusys Therapeutics
Purchase price allocation:
Cash and cash equivalents		$ 5,719,899
Contract receivables		24,526,232
Inventory		5,844,000
Prepaid expenses and other current assets		1,905,490
Intangible asset - definite-lived (Note 7)		9,700,000
Property and equipment		50,224
Operating lease right of use assets		352,906
Other assets		326,249
Total assets acquired		48,425,000
Accounts payable		(204,794)
Accrued expenses and other current liabilities		(5,155,363)
Operating lease obligations		(352,906)
Deferred income tax liability		(3,326,000)
Total liabilities assumed		(9,039,063)
Net assets acquired and liabilities assumed		39,385,937
Goodwill		3,467,748
Total estimated purchase consideration		$ 42,853,685
Total revenue of acquiree from acquisition date	6,000,000.0
Net loss of acquiree from acquisition date	$ 3,900,000